At The British Pharmacological Society's Pharmacology Meeting!

December 6, 2024

We’re thrilled to announce that Ian Knowles, our Head of Respiratory, and Christopher Ireson, our Head of Oncology, will be attending The British Pharmacological Society's annual Pharmacology meeting!

📅 When: 10-12th December 2024

📍Where: (https://www.miceconciergeme.com/pharmacology-2024)

Ian and Chris are excited to connect with attendees to discuss innovations in pharmacology and explore opportunities for future collaborations. Whether you’re working in respiratory, oncology, or other therapeutic areas, they’d be delighted to hear about your projects and share how Pharmidex can support your research and development goals.

💡 Let’s shape the future of pharmacology together!

#Pharmidex #Pharmacology2024 #Collaboration #Oncology #Respiratory #Innovation

< Older Post

Newer Post >

Welcome to Pharmidex, Grace!

November 5, 2025

We’re excited to welcome Grace Horne as our new Bioanalytical Scientist! 🎉 Grace brings great enthusiasm and passion for science, and we’re confident she’ll make a fantastic contribution to our team. Welcome aboard, Grace, we’re thrilled to have you with us! 💜

Pharmidex at the DDW Turning Science into Business Symposium

November 4, 2025

We’re pleased to share that Janette Dalay Robertson , Business Development Manager at Pharmidex , will attend the DDW Turning Science into Business Symposium 2025 on Tuesday, 4th November, at the The Francis Crick Institute , London. Janette looks forward to connecting with industry leaders and exploring new collaboration opportunities.

Pharmidex at the BMCS New Approaches to the Treatment of Parkinson’s

November 3, 2025

We’re delighted to announce that Pharmidex will present our poster "Driving breakthroughs in Parkinson’s & neurodegeneration research” at the upcoming RSC BMCS meeting. With over 23 years of CNS expertise, we support biopharma partners in developing new therapies for Parkinson’s disease and tauopathies, through: 🔹 Parkinson’s & neurodegeneration models 🔹 Transgenic CNS lines (incl. 5xFAD) 🔹 Biomarker & BBB penetration studies Join us in Cambridge to explore how our GLP-accredited CNS platforms accelerate discovery and development.